Adenine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Adenine: From No Documented Indication to Drug-Induced Osteoporosis
One-Sentence Summary
Adenine is a purine base that is currently listed in the US as liquid products, but the records give no approved indication. The TxGNN model predicts it may be relevant to drug-induced osteoporosis, but 0 clinical trials and 0 publications actually support this. The one registered trial found is an unrelated kidney disease registry, and the four papers found describe purine-analog drugs that cause bone damage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the records |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.16% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 2 (license numbers not recorded) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. No original indication is recorded either, so there is no established use to build a mechanistic bridge from.
The score is high (0.99), but the supplied evidence does not link adenine to treating or preventing drug-induced osteoporosis. The retrieved literature is about adenine-nucleotide-analog antivirals such as adefovir and tenofovir. These drugs are associated with bone toxicity, which is the opposite of a therapeutic effect. The graph signal most likely reflects network proximity to these purine-analog drugs, not a true therapeutic relationship.
One further point comes from general background knowledge, not from the supplied data, and has not been verified here. Adenine at high doses is a known experimental nephropathy inducer in rodents. That raises a safety question for any bone-related use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06065852 | N/A | Recruiting | 35,000 | National registry of rare kidney diseases (RaDaR), collecting data for guidelines and audits. It does not test adenine or any intervention and does not address drug-induced osteoporosis (relevance grade C, no usable evidence). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22943210 | 2012 | Review | Expert Opin Drug Metab Toxicol | Pharmacokinetics/pharmacodynamics of emtricitabine/tenofovir in HIV infection. Not about osteoporosis treatment. |
| 41924521 | 2026 | Case report | Front Endocrinol | Long-term adefovir dipivoxil caused Fanconi syndrome and hypophosphatemic osteomalacia and osteoporosis in a 67-year-old woman. The drug caused the bone damage. |
| 31026554 | 2019 | Preclinical (rat) | J Ethnopharmacol | Xian-Ling-Gu-Bao, an herbal formula used for osteoporosis, induced liver injury in rats through inflammatory and oxidative stress. Unrelated to adenine. |
| 20026012 | 2010 | In vitro | Biochem Biophys Res Commun | Tenofovir exposure altered gene expression (Gnas, Got2, Snord32a) in primary osteoclasts, a possible mechanism for drug-induced bone loss. |
None of these studies tests adenine.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not listed | Adenine (Professional Complementary Health Formulas) | Liquid | Not stated |
| Not listed | Adenine 3X (Energique, Inc.) | Liquid | Not stated |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction records were found for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (evidence level L5). No trial or paper supports adenine for drug-induced osteoporosis, and the retrieved literature points to bone toxicity from related purine analogs. There is also no recorded original indication, mechanism, or safety information.
To proceed, the following is needed:
- The package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data (for example from DrugBank) to test whether any real link to bone metabolism exists
- Direct evidence on adenine and bone health, such as preclinical or clinical studies
- An assessment of the rodent nephropathy signal and its relevance to human dosing
- Confirmation of what the two listed liquid products are and their regulatory status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.